Ballicules.com

Zavegepant

ZAVZPRET

Zavegepant ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Zavegepant ballicule
Zavegepant ZAVZPRET mascot mnemonic cartoon
Visual mnemonic: Zavegepant mascot
“Savage print pants”

What it isIntranasal CGRP receptor antagonist; acute migraine.

Why this oneThe only nasal gepant, so it works when vomiting prevents oral dosing and it acts within fifteen minutes.

What limits itDysgeusia is common and distinctive. Nasal discomfort; cost and access.

Zavegepant molecular structure (skeletal formula)
Molecular structure: Zavegepant

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Acute treatment of migraine (with or without aura)adult10 mg PRN10 mg PRN10 mg/24h

Renal No adjustment if CLcr ≥30 mL/min; avoid if CLcr <30 mL/min

Hepatic No adjustment mild-moderate (Child-Pugh A/B); avoid in severe (Child-Pugh C)

Max 10 mg (one spray) per 24 h; safety of treating >8 migraines per 30 days not established

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy No adequate human data; no adverse developmental effects in animals

Lactation No human milk data; weigh benefits against clinical need

Cost

Zavegepant (ZAVZPRET)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/unitbrand $/unitCostPlus
10 mg/spraynasal sprayper unit—$189.80/eanot offered

Generic entry2031 est.

NO BOXED WARNINGS

Principal riskDysgeusia; nasal discomfort

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityAgent-specific vascular, serotonergic or hepatic risks; acute overdose is usually limited outside ergot or cardiovascular agents.

Open Zavegepant in the interactive console ↗